Tesofensine: A Non-Peptide Triple Monoamine Reuptake Inhibitor in Metabolic Research

Not a peptide at all, tesofensine is a small molecule that inhibits reuptake at three monoamine transporters at once — those for norepinephrine, dopamine and serotonin. Development started with neurodegenerative disease as the target, and appetite observations surfacing in those early studies steered it into metabolic research. Of everything in our fat-loss range it is the sole compound working through central monoamine pharmacology, which makes it both an unusual research tool and the one demanding the most careful handling. Research-grade tesofensine is supplied as 0.5 mg capsules, for laboratory use only.

Defining tesofensine

Presynaptic terminals carry transporters — NET, DAT and SERT — whose job is to retrieve neurotransmitter after release. Block one and its neurotransmitter sits longer, and at higher concentration, in the cleft. The drugs most people recognise in this space are selective: SERT for the SSRIs, NET and DAT for certain ADHD medicines. This compound, designated NS2330 in the literature, blocks the set, which is what earns it the label triple reuptake inhibitor.

Structurally it is a phenyltropane derivative, a family that includes several transporter ligands used as pharmacological probes. Its molecular weight is 262.19 g/mol and its CAS number 402856-42-2. Nothing about it relates to peptides, and none of the analytical, storage or reconstitution habits of peptide work carry over.

Origin and structure

• Class of compound. A non-peptide phenyltropane small molecule, originating in a central nervous system discovery programme.
• Identifiers. Molecular weight 262.19 g/mol; CAS 402856-42-2.
• Targets. The transporters for norepinephrine, dopamine and serotonin, with reported potency greatest at NET and DAT and lower at SERT.
• Supplied format. Oral capsules of 0.5 mg each, in bottles of 30 or 60 — not lyophilized vials, since a stable crystalline small molecule has no need of freeze-drying.

The proposed mechanism

Preclinical reports attribute the feeding and appetite effects to higher synaptic norepinephrine and dopamine within hypothalamic and mesolimbic circuits. In the arcuate nucleus and neighbouring structures, noradrenergic and dopaminergic signalling modulates intake, while dopamine in reward pathways bears on the motivational aspect of eating rather than on hunger itself. Rodent work has described lower food intake and altered body composition, with some studies also reporting changes in energy expenditure alongside intake.

Since the mechanism is central and monoaminergic instead of peripheral and metabolic, this compound sits in a different experimental class from incretin agonists such as semaglutide or enzyme inhibitors such as 5-Amino-1MQ. It answers questions about neural control of feeding, and studies that combine a monoaminergic with a peripheral mechanism exist precisely because each addresses a separate limb of the same system. Wider context is in the brain and neuropeptide research hub.

Two aspects of the transporter profile should shape experimental use. The first is that potency is not the same at all three carriers, so at any given occupancy the composite effect is a weighted blend rather than uniform blockade — behavioural readouts taken across a concentration range may therefore reflect a different transporter mixture at each point. The second is that occupancy at monoamine transporters reverses slowly compared with receptor binding, so washout from a cell or tissue preparation takes longer than intuition suggests. Protocols built on an assumption of quick reversibility, or that lump observations from a broad concentration range together as though a single mechanism operated throughout, will be hard to interpret.

What has been studied

• Transporter pharmacology. Uptake inhibition and radioligand binding assays at NET, DAT and SERT, which set out the potency profile that defines the molecule.
• Rodent work. Intake and body composition in obesity models, microdialysis quantifying extracellular monoamines in defined brain regions, and behavioural studies of motivation and reward.
• Clinical trials in humans. Phase 2 obesity trials were run and reported weight outcomes, while the earlier Parkinson disease and Alzheimer disease trials — the original indications — missed their endpoints. No United States approval came out of the metabolic programme.
• Cardiovascular findings. Trials reported higher heart rate and blood pressure, a documented result and a direct pharmacological consequence of more synaptic norepinephrine. Our specification sheet names this as a known safety signal.

For anyone assessing the compound as a research tool, the development history carries its own lesson. When a molecule misses its original neurological endpoints and is redeployed on the strength of an incidental observation, a particular evidential risk follows: the metabolic hypothesis emerged from trials designed to test something else and has never been confirmed independently to approval standard. None of this makes the pharmacology wrong — transporter blockade is well characterised — but the step from transporter occupancy to any whole-organism outcome should be treated as an open question, and comparator arms based on better-validated mechanisms are worth building in wherever the design permits.

Presentations available

The tesofensine product page lists the sizes, within the fat-loss and metabolic collection and the broader research compounds range.

Handling and storage at the bench

Nothing has to be reconstituted. The compound arrives as a solid-format capsule and is kept sealed, dry, dark and at room temperature — the opposite of the minus 20 degrees Celsius regime lyophilized peptides demand. Solution experiments require extracting the capsule contents and allowing for the excipient matrix, because the fill includes bulking agents that are not active substance. That extraction creates a quantitation problem raw powder would avoid, and any laboratory planning work in solution should design around it.

One note from our specification sheet deserves emphasis: this is a centrally active compound and calls for the usual controlled-laboratory precautions. A peptide with little absorption by the oral route and no central action is forgiving; an orally active monoamine reuptake inhibitor is not, so storage should be secure and access restricted.

Purity, the COA and how to read it

A certificate covering a capsule product addresses a different question from one covering bulk chemical. It ought to establish the identity and purity of the active substance and, preferably, content uniformity — how much active substance is actually in each capsule, which at a 0.5 mg fill is the analytically hard part. For a synthetic small molecule, identity by mass spectrometry and, where offered, NMR is the appropriate evidence; purity by HPLC refers to the active substance rather than the capsule as a whole. There is no counterpart here to net peptide content. See how to read a COA.

One real advantage of this compound is how well it connects to the wider transporter literature. Monoamine transporter pharmacology is exceptionally well mapped, with selective reference ligands available for each carrier, so a study using tesofensine can be tied to a substantial established body of work — something impossible for peptides whose receptor has never been found. Where the question concerns what happens when several transporters are blocked simultaneously rather than one, that existing comparator set is what makes the design interpretable, and it belongs in the panel from the outset rather than as an afterthought.

Regulatory position

No approval as a medicine exists for tesofensine in the United States. Its weight-management development programme did not secure US approval, and the earlier neurology programme missed its endpoints. Status elsewhere varies, which changes nothing about the research material sold here: it is supplied as a laboratory reference chemical. Given central activity together with the documented heart rate and blood pressure signal, the research-use restriction on this compound marks a real safety boundary rather than a formality.

Related compounds and comparisons

Elsewhere in the metabolic range, the mechanistically different options are the enzyme inhibitor 5-Amino-1MQ and the transcriptional agonist SLU-PP-332 — set against each other in 5-Amino-1MQ vs SLU-PP-332. Peripheral peptide mechanisms are gathered in the GLP-1 and incretin collection, and the field as a whole in the metabolic research overview.